Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch™).

Fernando GJP, Hickling J, Jayashi Flores CM, Griffin P, Anderson CD, Skinner SR, Davies C, Witham K, Pryor M, Bodle J, Rockman S, Frazer IH, Forster AH.

Vaccine. 2018 Jun 18;36(26):3779-3788. doi: 10.1016/j.vaccine.2018.05.053. Epub 2018 May 17.

2.

Report on WHO meeting on immunization in older adults: Geneva, Switzerland, 22-23 March 2017.

Teresa Aguado M, Barratt J, Beard JR, Blomberg BB, Chen WH, Hickling J, Hyde TB, Jit M, Jones R, Poland GA, Friede M, Ortiz JR.

Vaccine. 2018 Feb 8;36(7):921-931. doi: 10.1016/j.vaccine.2017.12.029. Epub 2018 Jan 12.

3.

Meeting report: Initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics, March 2017.

Gottlieb SL, Giersing BK, Hickling J, Jones R, Deal C, Kaslow DC; HSV Vaccine Expert Consultation Group.

Vaccine. 2017 Dec 7. pii: S0264-410X(17)31492-5. doi: 10.1016/j.vaccine.2017.10.084. [Epub ahead of print]

PMID:
29224963
4.

Report on eighth WHO meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses: Chicago, USA, 23-24 August 2016.

Ortiz JR, Hickling J, Jones R, Donabedian A, Engelhardt OG, Katz JM, Madhi SA, Neuzil KM, Rimmelzwaan GF, Southern J, Spiro DJ, Hombach J.

Vaccine. 2018 Feb 8;36(7):932-938. doi: 10.1016/j.vaccine.2017.11.061. Epub 2017 Dec 6.

5.

Enhanced hip fracture management: use of statistical methods and dataset to evaluate a fractured neck of femur fast track pathway-pilot study.

Gilchrist N, Dalzell K, Pearson S, Hooper G, Hoeben K, Hickling J, McKie J, Yi M, Chamberlain S, McCullough C, Gutenstein M.

N Z Med J. 2017 May 12;130(1455):91-101.

PMID:
28494481
6.

Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5-7 May 2014.

Cox NJ, Hickling J, Jones R, Rimmelzwaan GF, Lambert LC, Boslego J, Rudenko L, Yeolekar L, Robertson JS, Hombach J, Ortiz JR.

Vaccine. 2015 Nov 27;33(48):6503-10. doi: 10.1016/j.vaccine.2015.10.014. Epub 2015 Oct 23.

PMID:
26478203
7.

Intradermal delivery of vaccines: potential benefits and current challenges.

Hickling JK, Jones KR, Friede M, Zehrung D, Chen D, Kristensen D.

Bull World Health Organ. 2011 Mar 1;89(3):221-6. doi: 10.2471/BLT.10.079426. Epub 2011 Jan 5.

8.

Thermostable formulations of a hepatitis B vaccine and a meningitis A polysaccharide conjugate vaccine produced by a spray drying method.

Chen D, Kapre S, Goel A, Suresh K, Beri S, Hickling J, Jensen J, Lal M, Preaud JM, Laforce M, Kristensen D.

Vaccine. 2010 Jul 12;28(31):5093-9. doi: 10.1016/j.vaccine.2010.04.112. Epub 2010 May 15.

PMID:
20478345
9.

Simultaneous modelling of the Michaelis-Menten kinetics of paracetamol sulphation and glucuronidation.

Reith D, Medlicott NJ, Kumara De Silva R, Yang L, Hickling J, Zacharias M.

Clin Exp Pharmacol Physiol. 2009 Jan;36(1):35-42. doi: 10.1111/j.1440-1681.2008.05029.x. Epub 2008 Aug 26.

PMID:
18759860
10.

Topographic distribution of bacteria associated with oral malodour on the tongue.

Allaker RP, Waite RD, Hickling J, North M, McNab R, Bosma MP, Hughes FJ.

Arch Oral Biol. 2008 Apr;53 Suppl 1:S8-S12. doi: 10.1016/S0003-9969(08)70003-7.

PMID:
18460402
11.

Control of oral malodour by dentifrices measured by gas chromatography.

Newby EE, Hickling JM, Hughes FJ, Proskin HM, Bosma MP.

Arch Oral Biol. 2008 Apr;53 Suppl 1:S19-25. doi: 10.1016/S0003-9969(08)70005-0.

PMID:
18460400
12.

Private companies and GPs: An inconvenient truth.

Hickling JA.

BMJ. 2008 Mar 15;336(7644):574. doi: 10.1136/bmj.39514.463356.80. No abstract available.

13.

Comparative safety and efficacy of two high dose regimens of oral paracetamol in healthy adults undergoing third molar surgery under local anaesthesia.

Zacharias M, De Silva RK, Hickling J, Medlicott NJ, Reith DM.

Anaesth Intensive Care. 2007 Aug;35(4):544-9.

14.

Phased in smoke-free workplace laws: impact in grass-roots pubs and clubs in South Australia.

Miller CL, Hickling JA.

Health Promot J Austr. 2007 Apr;18(1):26-32.

PMID:
17501708
15.
16.
17.

Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7).

Davidson EJ, Faulkner RL, Sehr P, Pawlita M, Smyth LJ, Burt DJ, Tomlinson AE, Hickling J, Kitchener HC, Stern PL.

Vaccine. 2004 Jul 29;22(21-22):2722-9.

PMID:
15246603
18.

Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination.

Smyth LJ, Van Poelgeest MI, Davidson EJ, Kwappenberg KM, Burt D, Sehr P, Pawlita M, Man S, Hickling JK, Fiander AN, Tristram A, Kitchener HC, Offringa R, Stern PL, Van Der Burg SH.

Clin Cancer Res. 2004 May 1;10(9):2954-61.

19.

Domestic violence in South Australia: a population survey of males and females.

Grande ED, Hickling J, Taylor A, Woollacott T.

Aust N Z J Public Health. 2003 Oct;27(5):543-50.

PMID:
14651403
20.

Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia.

Baldwin PJ, van der Burg SH, Boswell CM, Offringa R, Hickling JK, Dobson J, Roberts JS, Latimer JA, Moseley RP, Coleman N, Stanley MA, Sterling JC.

Clin Cancer Res. 2003 Nov 1;9(14):5205-13.

21.

Measuring human T-lymphocyte function.

Hickling JK.

Expert Rev Mol Med. 1998 Oct 13;1998:1-20. doi: 10.1017/S1462399498000313.

PMID:
14585132
22.

Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.

Davidson EJ, Boswell CM, Sehr P, Pawlita M, Tomlinson AE, McVey RJ, Dobson J, Roberts JS, Hickling J, Kitchener HC, Stern PL.

Cancer Res. 2003 Sep 15;63(18):6032-41.

23.

Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.

Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A, Adams M, Onon TS, Bauknecht T, Wagner U, Kroon K, Hickling J, Boswell CM, Stacey SN, Kitchener HC, Gillard J, Wanders J, Roberts JS, Zwierzina H.

Clin Cancer Res. 2002 Dec;8(12):3676-85.

24.

Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine.

de Jong A, O'Neill T, Khan AY, Kwappenberg KM, Chisholm SE, Whittle NR, Dobson JA, Jack LC, St Clair Roberts JA, Offringa R, van der Burg SH, Hickling JK.

Vaccine. 2002 Oct 4;20(29-30):3456-64.

PMID:
12297390
25.

The barriers to effective management of heart failure in general practice.

Hickling JA, Nazareth I, Rogers S.

Br J Gen Pract. 2001 Aug;51(469):615-8.

26.

Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens.

van der Burg SH, Kwappenberg KM, O'Neill T, Brandt RM, Melief CJ, Hickling JK, Offringa R.

Vaccine. 2001 Jun 14;19(27):3652-60.

PMID:
11395199
27.

Herpes virus-specific immune responses in individuals experiencing recurrent genital herpes.

Boswell CM, Duncan IA, Uttridge J, Sonnex C, Hickling JK.

Biochem Soc Trans. 1997 May;25(2):278S. No abstract available.

PMID:
9191322
28.

Generation of a primary immune response to a genetically inactivated (DISC) herpes simplex virus and wild type virus.

Hill S, Zhang X, Boursnell ME, Shields JG, Ricciardi-Castagnoli P, Hickling JK.

Biochem Soc Trans. 1997 May;25(2):200S. No abstract available.

PMID:
9191244
29.

Cancer vaccines.

Hickling J.

Mol Med Today. 1997 Apr;3(4):144-5. No abstract available.

PMID:
9134526
30.

Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer.

Boursnell ME, Rutherford E, Hickling JK, Rollinson EA, Munro AJ, Rolley N, McLean CS, Borysiewicz LK, Vousden K, Inglis SC.

Vaccine. 1996 Nov;14(16):1485-94.

PMID:
9014288
31.

A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.

Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D, Evans AS, Adams M, Stacey SN, Boursnell ME, Rutherford E, Hickling JK, Inglis SC.

Lancet. 1996 Jun 1;347(9014):1523-7.

PMID:
8684105
32.
33.

Strategies for studying mouse and human immune responses to human papillomavirus type 16.

Beverley PC, Sadovnikova E, Zhu X, Hickling J, Gao L, Chain B, Collins S, Crawford L, Vousden K, Stauss HJ.

Ciba Found Symp. 1994;187:78-86; discussion 86-96.

PMID:
7540971
34.

A method for rapid screening of recombinant proteins for recognition by T lymphocytes.

Hickling JK, Jones KR, Yuan B, Rothbard JB, Bülow R.

Eur J Immunol. 1992 Aug;22(8):1983-7.

PMID:
1379182
35.
36.

Human T cell responses to human papillomavirus type 16 L1 and E6 synthetic peptides: identification of T cell determinants, HLA-DR restriction and virus type specificity.

Strang G, Hickling JK, McIndoe GA, Howland K, Wilkinson D, Ikeda H, Rothbard JB.

J Gen Virol. 1990 Feb;71 ( Pt 2):423-31.

PMID:
1689768
37.

Peptides recognized by class I restricted T cells also bind to MHC class II molecules.

Hickling JK, Fenton CM, Howland K, Marsh SG, Rothbard JB.

Int Immunol. 1990;2(5):435-41.

PMID:
2085488
38.
39.

Human cytomegalovirus-specific cytotoxic T cells: their precursor frequency and stage specificity.

Borysiewicz LK, Graham S, Hickling JK, Mason PD, Sissons JG.

Eur J Immunol. 1988 Feb;18(2):269-75.

PMID:
2832181
41.

Lumbar traction: a double-blind controlled study for sciatica.

Mathews JA, Hickling J.

Rheumatol Rehabil. 1975 Nov;14(4):222-5.

PMID:
1105752
42.

Relax and recover.

Graveling B, Hickling JE, Pratt LG, Thurston M, Wrenn JC.

Nurs Times. 1972 Aug 10;68(32):996-8. No abstract available.

PMID:
5045343
43.

Spinal traction technique.

Hickling J.

Physiotherapy. 1972 Feb 10;58(2):58-63. No abstract available.

PMID:
4668979
44.

Abnormalities in passive movement: diagrammatic representation.

Hickling J, Maitland GD.

Aust J Physiother. 1970 Mar;16(1):13-31. doi: 10.1016/S0004-9514(14)61086-2.

45.

Abnormalities in passive movement: diagrammatic representation.

Hickling J, Maitland GD.

Physiotherapy. 1970 Mar;56(3):105-14. No abstract available.

PMID:
4191818
46.

Natural history of prostatic obstruction. A prospective survey.

Craigen AA, Hickling JB, Saunders CR, Carpenter RG.

J R Coll Gen Pract. 1969 Oct;18(87):226-32. No abstract available.

47.

LUMBAR DISC LESIONS: THE PHYSIOTHERAPIST'S PART.

HICKLING J.

Physiotherapy. 1964 Sep;50:304-6. No abstract available.

PMID:
14206580
48.

A DEFENCE OF OUR LIMITATIONS.

HICKLING J.

Physiotherapy. 1963 Sep;49:291-3. No abstract available.

PMID:
14052383
49.

Manipulation.

HICKLING J.

Physiotherapy. 1960 Jun 10;46:160-5. No abstract available.

PMID:
13852308
50.

Soft tissue lesions: localization and deep massage.

HICKLING J.

Physiotherapy. 1957 May;43(5):138-42. No abstract available.

PMID:
13431445

Supplemental Content

Loading ...
Support Center